Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo Pietrantonio

Showing results (1-10 of 323) with videos related to

Pageof 33
Sort By:
Recenti Progressi in Medicina|December 20, 2018
[Perioperative treatment with FOLFIRI plus aflibercept in a patient with RAS and BRAF wild-type, left-sided colon cancer, with early relapse following adjuvant oxaliplatin- based treatment due to potentially resectable liver metastases]Filippo Pietrantonio
Recenti Progressi in Medicina|December 20, 2018
[Second-line treatment with FOLFIRI plus aflibercept in a patient with right-sided, BRAF mutated metastatic colon cancer.]Filippo Pietrantonio
Recenti Progressi in Medicina|December 20, 2018
[Treatment with FOLFIRI plus aflibercept in a patient with RAS and BRAF wild-type, right-sided colon cancer and potentially resectable liver metastases]Filippo Pietrantonio
Tumori|September 21, 2016
How the lab is changing our view of colorectal cancerChiara Cremolini, Filippo Pietrantonio
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2023
Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal CancerGiovanni Randon, Filippo Pietrantonio
Med (New York, N.Y.)|June 12, 2026
Chemoimmunotherapy enables adaptive strategies in locally advanced MSS colorectal cancerFilippo Ghelardi, Filippo Pietrantonio
Journal for Immunotherapy of Cancer|June 24, 2021
Author response to Colle <i>et al</i>Giovanni Fucà, Francesca Corti, Filippo Pietrantonio
Cancer Cell|October 3, 2025
Bringing immunotherapy to clinical practice in dMMR/MSI-high colon cancerGiovanni Randon, Isacco Montroni, Filippo Pietrantonio
Cancer Treatment Reviews|March 15, 2021
Microsatellite instability in Gastric Cancer: Between lights and shadowsElisabetta Puliga, Simona Corso, Filippo Pietrantonio, et al.
The Oncologist|October 18, 2012
Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancerEduardo Díaz-Rubio, Filippo Pietrantonio, Filippo de Braud
Pageof 33

Showing results (1-10 of 323) with videos related to

Sort By:
Pageof 33
Recenti Progressi in Medicina|December 20, 2018
[Perioperative treatment with FOLFIRI plus aflibercept in a patient with RAS and BRAF wild-type, left-sided colon cancer, with early relapse following adjuvant oxaliplatin- based treatment due to potentially resectable liver metastases]Filippo Pietrantonio
Recenti Progressi in Medicina|December 20, 2018
[Second-line treatment with FOLFIRI plus aflibercept in a patient with right-sided, BRAF mutated metastatic colon cancer.]Filippo Pietrantonio
Recenti Progressi in Medicina|December 20, 2018
[Treatment with FOLFIRI plus aflibercept in a patient with RAS and BRAF wild-type, right-sided colon cancer and potentially resectable liver metastases]Filippo Pietrantonio
Tumori|September 21, 2016
How the lab is changing our view of colorectal cancerChiara Cremolini, Filippo Pietrantonio
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2023
Towards Multiomics-Based Dissection of Anti-EGFR Sensitivity in Colorectal CancerGiovanni Randon, Filippo Pietrantonio
Med (New York, N.Y.)|June 12, 2026
Chemoimmunotherapy enables adaptive strategies in locally advanced MSS colorectal cancerFilippo Ghelardi, Filippo Pietrantonio
Journal for Immunotherapy of Cancer|June 24, 2021
Author response to Colle <i>et al</i>Giovanni Fucà, Francesca Corti, Filippo Pietrantonio
Cancer Cell|October 3, 2025
Bringing immunotherapy to clinical practice in dMMR/MSI-high colon cancerGiovanni Randon, Isacco Montroni, Filippo Pietrantonio
Cancer Treatment Reviews|March 15, 2021
Microsatellite instability in Gastric Cancer: Between lights and shadowsElisabetta Puliga, Simona Corso, Filippo Pietrantonio, et al.
The Oncologist|October 18, 2012
Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancerEduardo Díaz-Rubio, Filippo Pietrantonio, Filippo de Braud
Pageof 33